anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The complex interplay between the gut microbiota, cancer treatments and patient characteristics has emerged as a significant area of research. This study sought to examine these relationships in the context of colorectal cancer (CRC).A comprehensive search of relevant studies was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines and the Cochrane Handbook for Systematic Reviews of Interventions. The studies included a variety of treatment modalities and microbiological parameters. A data extraction form, designed specifically for this review, was used to assess a range of variables across all studies.The analysis revealed a multifaceted interaction between the gut microbiota, genetic factors and treatment outcomes. Elderly patients with CRC frequently received single-agent chemotherapy, with outcomes that were comparable to those of younger patients. The presence of tumorigenic bacteria, including Escherichia coli and Bacteroides fragilis, was associated with early colon neoplasia. Additionally, an abundance of Fusobacterium spp. was observed in colonic adenomas, contributing to a pro-inflammatory environment. Although the FcγRIIIa-158 V/V genotype was associated with higher cetuximab-mediated antibodydependent cellular cytotoxicity (ADCC), no direct influence of FcγR polymorphisms on treatment response was noted. Furthermore, the combination of programmed cell death protein-1 (PD-1), BRAF and MEK inhibition showed favorable response rates. The gut microbiome, especially the presence of Fusobacterium spp., had a notable influence on the therapeutic response in CRC.These findings underscore the role of the gut microbiota and genetic factors in cancer treatment outcomes, emphasizing the potential of a holistic approach to cancer management. Future research should exploit these findings in order to develop microbiota-modulating strategies and personalized medicine approaches for the purpose of improving the efficacy of cancer treatment.
OBJECTIVE: The aim of this study was to determine whether clinical efficacy and reported adverse effects (AEs) of the newer antiseizure medications (ASMs) brivaracetam (BRV), lacosamide (LCM), and perampanel (PER) have been associated with plasma levels of these ASMs. We also investigated whether plasma levels outside the reference range has led to dose adjustments.
METHODS: Plasma levels of 300 people with epilepsy (PWE) seen at our tertiary epilepsy center were determined by liquid chromatography-tandem mass spectrometry. PWE received BRV (n = 100), LCM (n = 100), or PER (n = 100), in most cases in polytherapy. Demographic and clinical data were retrospectively analyzed and related to plasma levels. Clinical efficacy of BRV, LCM, or PER was assessed retrospectively by comparing seizure frequency at the time of current blood draw with seizure frequency at the time of first administration. AEs were also recorded and, if reported, compared retrospectively with the time of first administration.
RESULTS: No significant associations were found between plasma levels of BRV, LCM, or PER and seizure freedom (BRV, p = 1.000; LCM, p = .243; PER, p = .113) or responder status (BRV, p = .118; LCM, p = .478; PER, p = .069) at presentation. There was also no pattern between plasma levels and the occurrence of AEs. In the majority of cases, drug levels outside the reference ranges have not led to adjustments in the daily doses of BRV (93.5%), LCM (93.9%), or PER (89.1%).
SIGNIFICANCE: Plasma levels at a given time point did not allow conclusions to be drawn about seizure control or the occurrence of AEs. Our findings indicate that efficacy and tolerability cannot be predicted based on averaged data from a single plasma measurement due to high interindividual variability. Instead, individual reference values should be established when sufficient clinical data are available, in line with the 2008 International League Against Epilepsy position paper on therapeutic drug monitoring.
Humans attain slower maximum velocity (vmax) on curves versus straight paths, potentially due to centripetal ground reaction force (GRF) production, and this depends on curve radius. Previous studies found GRF production differences between an athlete's inside versus outside leg relative to the center of the curve. Further, sprinting clockwise (CW) versus counterclockwise (CCW) slows vmax. We determined vmax, step kinematics and individual leg GRF on a straight path and on curves with 17.2 and 36.5 m radii for nine (8 male, 1 female) competitive sprinters running CW and CCW and compared vmax with three predictive models. We combined CW and CCW directions and found that vmax slowed by 10.0±2.4% and 4.1±1.6% (P<0.001) for the 17.2 and 36.5 m radius curves versus the straight path, respectively. vmax values from the predictive models were up to 3.5% faster than the experimental data. Contact length was 0.02 m shorter and stance average resultant GRF was 0.10 body weights (BW) greater for the 36.5 versus 17.2 m radius curves (P<0.001). Stance average centripetal GRF was 0.10 BW greater for the inside versus outside leg (P<0.001) on the 36.5 m radius curve. Stance average vertical GRF was 0.21 BW (P<0.001) and 0.10 BW (P=0.001) lower for the inside versus outside leg for the 17.2 and 36.5 m radius curves, respectively. For a given curve radius, vmax was 1.6% faster in the CCW compared with CW direction (P=0.003). Overall, we found that sprinters change contact length and modulate GRFs produced by their inside and outside legs as curve radius decreases, potentially limiting vmax.
PROBLEM TO BE SOLVED: To obtain a perfume compsn. which can prevent the degradation of a perfume and can maintain a stable perfume emission by compounding tocotrienol as the effective component into the same. SOLUTION: This compsn. contains tocotrienol as the effective component. Tocotrienol includes α-, β-, γ-, and δ-tocotrienols. All of them have their d-, l-, and dl-isomers, and all of the isomers and their mixtures can be used in this invention. Tocotrienol is compounded into the compsn. in an ant. of 0.01-1.0wt.% of the compsn. Tocotrienol can be obtd. by pressing a natural product, by the extraction or synthesis from a natural product, etc.; however, generally it is extracted from the seedcases and/or seeds of trees of the palm family.
This multicentre \& multicountry study is open and has 2 study groups at Visits 1 and 3 (HibMenC and LicMenC). An additional control group in the UK at the time of the second year follow-up for persistence (subjects aged 40-43 months primed with MenC conjugate and Hib vaccines in infancy with no subsequent booster dose, group NoBoost at Visit 2). These subjects will receive a Hib catch-up vaccine at 40-43 months of age. The subjects of groups HibMenC and LicMenC were randomized in the primary vaccination study 103974 and will not be further randomized. The subjects of group NoBoost will not be randomized. All subjects at the UK centre will receive Infanrix™-IPV at the second visit (i.e. 24 months after Menitorix booster or at 40-43 months of age). In addition, the subjects of group NoBoost will receive a Hib catch-up vaccine (Menitorix™) at the same visit.

Subjects of groups HibMenC and LicMenC will have 3 blood samples taken for immunogenicity analyses: at 12, 24 \& 48 months after the booster vaccination. Subjects of group NoBoost will have 1 blood sample taken for immunogenicity analyses at 40-43 months of age. 75 new subjects will be enrolled in this study (group NoBoost).
Tasigna has been shown to prolong cardiac ventricular repolarization as measured by the QT interval on the surface electrocardiogram (ECG) in a concentration-dependent manner [see Adverse Reactions (6.1), Clinical Pharmacology (12.2)]. Prolongation of the QT interval can result in a type of ventricular tachycardia called torsade de pointes, which may result in syncope, seizure, and/or death. Electrocardiograms should be performed at baseline, 7 days after initiation of Tasigna, and periodically as clinically indicated and following dose adjustments [see Dosage and Administration (2.4), Warnings and Precautions (5.12)]. 

Tasigna should not be used in patients who have hypokalemia, hypomagnesemia, or long QT syndrome. Before initiating Tasigna and periodically, test electrolyte, calcium, and magnesium blood levels. Hypokalemia or hypomagnesemia must be corrected prior to initiating Tasigna and these electrolytes should be monitored periodically during therapy [see Warnings and Precautions (5.12)].

Significant prolongation of the QT interval may occur when Tasigna is inappropriately taken with food and/or strong CYP3A4 inhibitors and/or medicinal products with a known potential to prolong QT. Therefore, coadministration with food must be avoided and concomitant use with strong CYP3A4 inhibitors and/or medicinal products with a known potential to prolong QT should be avoided [see Dosage and Administration (2.1), Drug Interactions (7.1, 7.2)]. The presence of hypokalemia and hypomagnesemia may further prolong the QT interval [see Warnings and Precautions (5.7, 5.12)].
Non-celiac gluten sensitivity (NCGS) is a condition where intestinal and extraintestinal symptoms are triggered by gluten ingestion in the absence of celiac disease and wheat allergy. Despite the great interest in NCGS, much remains unknown about the pathogenesis. Some studies seem to suggest that wheat components other than gluten (i.e. amylase/trypsine inhibitors, ATIs) can cause the symptoms, and therefore the term "non-celiac wheat sensitivity" (NCWS) has been proposed instead of NCGS. NCWS pathogenesis has been attributed to very different mechanisms: innate or adaptive immunity, incomplete digestion and/or absorption of fermentable oligosaccharides and disaccharides, monosaccharides and polyols, and, finally, psychological effect. In addition, it is believed that this condition is worldwide increasing, due to the evolution of wheat breeding (i.e. consumption of wheats with high gluten content), and that ancient wheats are better tolerated by NCWS patients than the modern ones. Therefore, the aim of the study is to determine whether the common belief regarding the fact that ancient wheats are better tolerated by NCWS patients than the modern ones is confirmed by scientific data, and to identify the wheat kernel components triggering this pathology. The availability of wheat materials with opposite characteristics, such as the period of development (ancient vs. modern), or the technological properties (cultivars with weak glutens vs. strong gluten), or the presence/absence of specific ATIs polypeptides, will allow to define the role played by these factors. The researchers take into consideration different tetraploid wheat genotypes derived from the Italian breeding activity carried out during the 20th century in comparison with landraces, primitive and old wheat cultivars previously cultivated and used mostly in Southern Italy for pasta and bread production, together with an experimental genetically modified (GM) wheat line expressing a lower amount of ATIs. For the purpose of the study, the collection has been subdivided into 5 groups, according to the breeding period. Wheat genotypes will be also evaluated for several parameters: protein content, gluten index, quantitative analysis of ATIs proteins by Mass Spectrometry, etc. The project has two objectives, related to the influence of wheat consumption on health: 1) extraction and testing of total kernel proteins, in order to evaluate the inflammatory response to gluten and non-gluten proteins by peripheral blood mononuclear cells (PBMC) and immunocytes extracted by the rectal mucosa of NCWS patients and healthy control subjects, and 2) clinically testing two wheat genotypes, selected on the basis of the previous in vitro studies, showing the highest and the lowest in vitro inflammatory response, in order to verify their effect in triggering NCWS symptoms.
FIELD: medicine, stomatology. SUBSTANCE: composition is made as dental pasta, powder, liquid agent, liquid for mouth gargle, cleansing agent for dental prostheses cleansing, chewing gum or hard candy. It has one or some components taken among abrasives, binding substances, wetting agents, surface-active substances, sources of fluoride ions, agents used against dental stone and sweeten agents. Composition has obligatory dimethicone copolyol taken among alkyl- and alkoxydimethicone copolyols of the formula:   where X is taken among hydrogen atom, alkyl, alkoxyl and acyl groups having about from 1 to 16 carbon atoms; Y is taken among alkyl and alkoxyl groups having about from 8 to 22 carbon atoms; n is about from 0 to 200; m is about from 1 to 40; q is about from 1 to 100; molecular mass of the residue (C 2 H 4 O-) x (C 3 H 6 O-) y X is about from 50 to 2000 Da; x and y have values that provide the ratio hydroxyethylene : hydroxypropylene is about from 100:0 to 0:100. Invention relates to also the use of dimethicone copolyol of the above given structural formula as an agent against dental deposit in oral composition that can be used for dental prostheses cleansing. Composition shows good physical indices of working ability in using, makes freshness sense into the mouth. Composition can be used for teeth and dental prostheses cleansing. EFFECT: enhanced activity against dental deposit and dental stone. 9 cl, 2 tbl
BACKGROUND: Atrial fibrillation is the most commonly observed cardiac rhythm disorder. Pulmonary vein isolation (PVI) is an effective treatment option to maintain sinus rhythm. This study evaluates the safety, efficacy, clinical outcomes and radiation exposures using a standardized single transseptal puncture (STP)-strategy.
METHODS: We analyzed data from patients who underwent our STP-ablation technique with transesophageal echocardiography (TEE) guidance at a university hospital and a regional tertiary health center in Switzerland between January 1, 2017, and May 30, 2022. Collected data included demographics, symptoms, echocardiography results, procedural details, complications and outcomes. Mean follow-up time was 21.4 ± 16 months.
RESULTS: The study population included 304 patients with a median age of 67 years, who had at least one ablation using our STP-approach. Among these, 248 (82 %) patients underwent de novo PVI with this technique. Ablation was successful in all patients with isolation of all pulmonary veins, with an average procedure duration of 120 min and an average fluoroscopy time of 3 min, resulting in a mean X-ray dose of 252 cGy × cm2. TEE guidance was performed in 235 (95 %) patients. During the first intervention, 17 complications occurred in 13 patients (5 %). After the first PVI, 135 (54 %) patients experienced no recurrence during the follow-up period. The one-year recurrence rate for atrial fibrillation requiring therapy was 30 %.
CONCLUSION: Our STP- approach demonstrated comparable success rates to traditional methods, with similar procedural durations, low radiation exposure and a low complication rate. Therefore, this method may offer procedural, economic and safety benefits without compromising efficacy or safety.
This is a 5-year prospective, longitudinal, observational study of all patients undergoing TIPS placement. The study will accrue patients until the goal of 1,000 subjects is reached. Subjects will be followed prospectively for up to a total of 5 years. Patients will be clinically managed by their local physicians per standard of care and no specific treatments or interventions will be dictated by their enrollment in this study. Patients will be consented to enroll in the study prior to TIPS placement or within 14 days after TIPS placement (such as in the event of emergent TIPS) and their pertinent clinical information will be then collected. Subjects may be consented electronically using REDCap eConsent or docusign. Pre-TIPS participants will be asked to complete a short set of questionnaires and one verbal assessment both pre-TIPS and post-TIPS during regularly scheduled visits with their treating hepatologist. Blood and rectal samples will be collected as optional procedures, and participation in these procedures will not affect participation in the study. Patients will be asked to consent to three different 5mL blood samples (total 15mL) at the time of TIPS from the peripheral, central, and portal venous circulation. A 5 ml peripheral sample will also be collected at months 1, 6, and 12 post-TIPS. The peripheral blood samples will occur either prior to TIPS (time 0) in the IR suite or at months 1, 6 and 12 post-TIPS. The central and portal venous blood sample will occur during the TIPS procedure in the IR suite. The total blood volume collection throughout the study will be 30mL. The rectal swab will be performed by the IR/ anesthesia team prior to the TIPS procedure in the IR suite. During the prospective post-TIPS period all medical records will be reviewed including clinical notes, laboratory values, radiographic results and medication changes and this data will be inputted into the database. Participants will be asked to also complete the same questionnaires regarding their quality of life and patient reported outcomes at prespecified timepoints post-TIPS, at a minimum 3 months and 12 months post-TIPS placement and then yearly thereafter. The hepatic encephalopathy assessments and AUDIT-C questionnaire will be conducted at month 1, 3, 6,12 and then yearly thereafter as part of their usual post-TIPS care.
Periodontitis is a common chronic inflammatory and destructive disease in the mouth and is considered to be associated with systemic diseases. Accumulating evidence has suggested that periodontitis is a risk factor for pulmonary diseases such as pneumonia, chronic obstructive pulmonary disease (COPD), asthma, coronavirus disease 2019 (COVID‑19) and lung cancer. The presence of common periodontal pathogens has been detected in samples from a variety of pulmonary diseases. Periodontal pathogens can be involved in lung diseases by promoting the adhesion and invasion of respiratory pathogens, regulating the apoptosis of respiratory epithelium and inducing overexpression of mucin and disrupting the balance of immune systemin respiratory epithelium cells. Additionally, measures to control plaque and maintain the health of periodontal tissue can decrease the incidence of respiratory adverse events. This evidence suggests a close association between periodontitis and pulmonary diseases. The present study aimed to review the clinical association between periodontitis and pneumonia, COPD, asthma, COVID‑19 and lung cancer, and propose a possible mechanism and potential role of periodontal pathogens in linking periodontal disease and lung disease. This could provide a direction for further research on the association between periodontitis and lung disease and provide novel ideas for the clinical diagnosis and treatment management of these two diseases.
Patients receive rilimogene-galvacirepvec SC on day 1 of course 1 and fowlpox-PSA-TRICOM vaccine SC on days 15, 29, 43, and 57 of course 1. Beginning on day 85 (day 1 of course 2), patients receive docetaxel IV over 1 hour on day 1 and prednisone PO BID on days 1-21. Treatment with docetaxel and prednisone repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
Patients with a new diagnosis of spondyloarthritis and indication of DMARD treatment without glucocorticoid treatment. Women should be premenopausal and men younger than 50 years.
FIELD: organic chemistry, medicine. SUBSTANCE: invention proposes new agent and a method of treatment or prophylaxis of erectile disorder in male animal involving man and for treatment or prophylaxis or sexual disorder in female. The first agent, for example, the compound of the general formula (I):   where radical values are indicated in the invention claims or its pharmaceutically acceptable salts or a pharmaceutical composition containing this compound which is an inhibitor of cGMP phosphodiesterase. The indicated agent is designated for intake by patient by per os route first. The compound of the general formula (I) or its pharmaceutically acceptable salts or a pharmaceutical composition containing this compound is proposed as an agent and a method of treatment or prophylaxis of sexual disorder in female. EFFECT: broadened pattern of agents of the indicated prescription. 14 cl
INTRODUCTION: Hypoxic ischaemic encephalopathy (HIE), a condition where the brain does not receive enough oxygen and/or blood flow around the time of birth, is associated with significant morbidity and mortality. Systemic circulation may be affected due to poor myocardial function. The cochlear hair cells are vulnerable to changes in microcirculation, which may occur in HIE predisposing to hearing loss. Therefore, all infants with HIE undergo neurodevelopmental surveillance after discharge to monitor for adverse neurodevelopment including speech and hearing problems. This study will examine the incidence of confirmed hearing loss in newborn infants with any stage of HIE (cases) and compare them with controls.
METHODS AND ANALYSIS: All infants diagnosed with any stage of HIE (cases) over a 12-year period (January 2010 to December 2021) will be examined. Controls were newborn infants without HIE who were admitted to the neonatal unit and received intensive care including antibiotics (control group 1) and stable infants in the postnatal ward who received antibiotics (eg, gentamicin) (control group 2). Controls matched for gestation, gender and birth weight will be selected from a similar time period. Infant details and hearing screening data will be gathered from prospectively entered BadgerNet and S4H system databases, respectively. Categorical data will be analysed using the χ2 test. Predictors for hearing loss will be performed using binary logistic regression analysis.
ETHICS AND DISSEMINATION: The study is approved by the Health and Care Research Wales (HCRW) Research Ethics Committee and the Health Research Authority (HRA) (reference 21/HRA/4506). The study findings will be presented at national/international conferences and published in peer-reviewed scientific journals.